Format
Items per page
Sort by

Send to:

Choose Destination

Results: 8

Cited In for PubMed (Select 8417553)

1.

Elevated monoamine oxidase a binding during major depressive episodes is associated with greater severity and reversed neurovegetative symptoms.

Chiuccariello L, Houle S, Miler L, Cooke RG, Rusjan PM, Rajkowska G, Levitan RD, Kish SJ, Kolla NJ, Ou X, Wilson AA, Meyer JH.

Neuropsychopharmacology. 2014 Mar;39(4):973-80. doi: 10.1038/npp.2013.297. Epub 2013 Oct 24.

2.

Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.

Aboukhatwa M, Dosanjh L, Luo Y.

Mol Neurodegener. 2010 Mar 12;5:10. doi: 10.1186/1750-1326-5-10.

3.
4.

Tackling partial response to depression treatment.

[No authors listed]

Prim Care Companion J Clin Psychiatry. 2009;11(4):155-62. doi: 10.4088/PCC.8133ah3c. No abstract available.

6.

The role of monoamine oxidase inhibitors in current psychiatric practice.

Fiedorowicz JG, Swartz KL.

J Psychiatr Pract. 2004 Jul;10(4):239-48.

7.

Trends in the development of new antidepressants. Is there a light at the end of the tunnel?

Pacher P, Kecskemeti V.

Curr Med Chem. 2004 Apr;11(7):925-43. Review.

8.

Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial.

Jarrett RB, Schaffer M, McIntire D, Witt-Browder A, Kraft D, Risser RC.

Arch Gen Psychiatry. 1999 May;56(5):431-7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk